Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DEB-TACE with or without apatinib for unresectable large hepatocellular carcinoma
ChiCTR2000041170Phase 4Recruiting
- Sponsor
- Department of Interventional Medicine, The First Affiliated Hospital of Zhengzhou University
- Start
- Jan 2021
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in hepatocellular carcinoma (HCC) comparing DEB-TACE combined with apatinib with DEB-TACE (2 arms). Primary endpoint: progression-free survival. Started Jan 2021; status: recruiting.
02
Drugs
Rivoceranibdoxorubicin
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2000041170.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000041170.